As patients with MS in the United States get older, questions about therapies shift from treatment to discontinuation. Drs Cross and Corboy discuss the DISCOMS trial to address these questions. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977033). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources The Prevalence of MS in the United States https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442006/pdf/NEUROLOGY2018886077.pdf Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) (DISCOMS) https://clinicaltrials.gov/ct2/show/NCT03073603 Stopping Disease-Modifying Therapy in Relapsing and Progressive Multiple Sclerosis https://journals.lww.com/co-neurology/Abstract/2021/08000/Stopping_disease_modifying_therapy_in_relapsing.18.aspx Discontinuation of Disease-Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study https://www.ninds.nih.gov/health-information/clinical-trials/discontinuation-disease-modifying-therapies-dmts-multiple-sclerosis-ms-extension-discoms-study North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) https://www.narcrms.org/ How MS Disability Is Measured https://www.webmd.com/multiple-sclerosis/disability-measured Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010264/pdf/fneur-12-647811.pdf Natalizumab Discontinuation in a Dutch Real-world Cohort https://www.sciencedirect.com/science/article/abs/pii/S2211034821002418 Factors Associated With Fingolimod Rebound: A Single Center Real-life Experience https://www.sciencedirect.com/science/article/abs/pii/S2211034821005459 Serious Safety Events in Rituximab-Treated Multiple Sclerosis and Related Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480911/

Ver todos los episodios